Torbay Pharmacy Manufacturing Unit appoints md

Dr Nick Frampton to run the unit

The UK’s South Devon Healthcare NHS Foundation Trust has appointed Dr Nick Frampton as managing director of the Torbay Pharmacy Manufacturing Unit (PMU), which produces licensed pharmaceuticals, pharmaceutical specials and medical devices.

Frampton joins the firm from Advanced Medical Solutions Group, where he was vice president of sales and marketing and contributed to a period of double-digit growth. He has formerly held quality, technical and commercial roles at West Pharmaceutical Services, Ernest Jackson and Banner Pharmacaps.

You may also like

Finance

NorthEdge invests in sterile injectable CMO to accelerate international growth

Private equity firm NorthEdge has invested in sterile injectable contract manufacturer and licence holder, Torbay Pharmaceuticals (Torbay), to support its next phase of international growth
Research & Development

Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform

Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
Finance

Lupin completes acquisition of VISUfarma from GHO to expand ophthalmology portfolio

The addition enhances Lupin's presence in Europe and includes a portfolio of more than 60 innovative eye health products, backed by a well-established commercial infrastructure
Manufacturing

BASF announces up to 20% price increase on pharmaceutical excipients and selected APIs

BASF Pharma Solutions has implemented an immediate global price adjustment of up to 20% across its pharmaceutical excipients and selected active pharmaceutical ingredients portfolio, citing rising energy and raw material costs
Research & Development

University of Exeter leads £4.5m Wellcome-funded initiative to develop bioimaging tools for fungal pathogens

An international collaboration spanning the universities of Exeter, Edinburgh and Cape Town has secured £4.5m to develop specialist bioimaging tools for WHO-priority fungal pathogens
Finance

Merck to acquire cancer biotech Terns Pharmaceuticals for $6.7bn

The purchase is the third multibillion-dollar acquisition for the pharma giant in the past year, as it moves to bolster its cancer portfolio ahead of its best-selling drug Keytruda losing patent protection in 2028
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Investing in the future of healthcare: from diagnostics innovation to scientific talent pipelines

Strategic UK investment in next-generation cancer diagnostics and cardiovascular research training is accelerating innovation, reducing barriers to adoption and building the multidisciplinary talent needed to deliver long-term improvements in patient outcomes and life sciences growth
Subscribe now